Continuous or persistent scant menstrual flow
Specialty: Gynecology and breast.
Why it occurs
- Depot progestin-induced endometrial dysfunction (continuous atrophic effect on the endometrium from subdermal etonogestrel implants or levonorgestrel IUDs causing minimal persistent low-quantity spotting)
- Tuberculous endometritis (chronic granulomatous infection by Mycobacterium tuberculosis that partially destroys the endometrial stroma, causing patchy endometrial atrophy)
- Mild Asherman syndrome (fine intrauterine adhesions that limit generalized endometrial shedding while maintaining minimal areas of chronic bleeding)
- Incomplete Sheehan syndrome (partial postpartum pituitary necrosis that causes suboptimal and sustained secretion of gonadotropins, resulting in minimal continuous estrogenic stimulation)
Initial workup
Quantitative determination of Beta-hCG in peripheral blood; high-resolution transvaginal ultrasound with power Doppler to measure endometrial thickness and evaluate irregular endometrial vascularization; office hysteroscopy with targeted endometrial biopsy; endometrial culture and PCR for Mycobacterium tuberculosis.
red flags
Slight persistent bleeding that appears in postmenopausal women (should be rigorously evaluated to rule out endometrial adenocarcinoma), or associated with prolonged secondary amenorrhea, active infertility, persistent chronic pelvic pain or evening low-grade fever.
Standard management
- Ethinylestradiol in low doses — 10-20 mcg daily for 10-14 days, useful to induce rapid proliferation of the endometrium and stop continuous scant bleeding in users of contraceptive implants
- Estrogen therapy combined with cyclical progestogens if secondary to atrophy due to central hypoestrogenism
- Specific four-drug antituberculous treatment if a granulomatous infectious cause is confirmed.
Educational guidance for study. It is NOT a prescription recommendation. The actual choice depends on the cause, the patient, and current guidelines.
- Area
- Gynecology and breast
- Listed causes
- 4
- Treatment options
- 3